Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
20176 | 410 | 37.8 | 88% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1432 | 7402 | THROMBOPOIETIN//ONCOSTATIN M//LEUKEMIA INHIBITORY FACTOR |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | INTERLEUKIN 11 | Author keyword | 45 | 41% | 21% | 86 |
2 | INTERLEUKIN 11 RECEPTOR | Author keyword | 27 | 92% | 3% | 11 |
3 | IL 11 | Author keyword | 22 | 38% | 11% | 45 |
4 | RECOMBINANT HUMAN INTERLEUKIN 11 | Author keyword | 15 | 71% | 3% | 12 |
5 | RHIL 11 | Author keyword | 5 | 63% | 1% | 5 |
6 | IL 11 RECEPTOR | Author keyword | 4 | 75% | 1% | 3 |
7 | GRP RECH CYTOKINES RECEPTEURS | Address | 4 | 41% | 2% | 7 |
8 | HUMAN INTERLEUKIN 11 | Author keyword | 2 | 67% | 0% | 2 |
9 | ADIPOGENESIS INHIBITORY FACTOR | Author keyword | 1 | 100% | 0% | 2 |
10 | GP130 TARGETING | Author keyword | 1 | 100% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | INTERLEUKIN 11 | 45 | 41% | 21% | 86 | Search INTERLEUKIN+11 | Search INTERLEUKIN+11 |
2 | INTERLEUKIN 11 RECEPTOR | 27 | 92% | 3% | 11 | Search INTERLEUKIN+11+RECEPTOR | Search INTERLEUKIN+11+RECEPTOR |
3 | IL 11 | 22 | 38% | 11% | 45 | Search IL+11 | Search IL+11 |
4 | RECOMBINANT HUMAN INTERLEUKIN 11 | 15 | 71% | 3% | 12 | Search RECOMBINANT+HUMAN+INTERLEUKIN+11 | Search RECOMBINANT+HUMAN+INTERLEUKIN+11 |
5 | RHIL 11 | 5 | 63% | 1% | 5 | Search RHIL+11 | Search RHIL+11 |
6 | IL 11 RECEPTOR | 4 | 75% | 1% | 3 | Search IL+11+RECEPTOR | Search IL+11+RECEPTOR |
7 | HUMAN INTERLEUKIN 11 | 2 | 67% | 0% | 2 | Search HUMAN+INTERLEUKIN+11 | Search HUMAN+INTERLEUKIN+11 |
8 | ADIPOGENESIS INHIBITORY FACTOR | 1 | 100% | 0% | 2 | Search ADIPOGENESIS+INHIBITORY+FACTOR | Search ADIPOGENESIS+INHIBITORY+FACTOR |
9 | GP130 TARGETING | 1 | 100% | 0% | 2 | Search GP130+TARGETING | Search GP130+TARGETING |
10 | INTERLEUKIN 11 ALPHA RECEPTOR | 1 | 100% | 0% | 2 | Search INTERLEUKIN+11+ALPHA+RECEPTOR | Search INTERLEUKIN+11+ALPHA+RECEPTOR |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEMATOPOIETIC CYTOKINE | 36 | 70% | 7% | 30 |
2 | IL 11 RECEPTOR | 32 | 85% | 4% | 17 |
3 | RECOMBINANT HUMAN INTERLEUKIN 11 | 29 | 35% | 17% | 68 |
4 | ADIPOGENESIS INHIBITORY FACTOR | 15 | 82% | 2% | 9 |
5 | MURINE INTERLEUKIN 11 | 15 | 82% | 2% | 9 |
6 | RHIL 11 GROWTH FACTOR | 15 | 77% | 2% | 10 |
7 | IL 11 | 13 | 44% | 5% | 22 |
8 | INTERLEUKIN 11 | 7 | 19% | 9% | 35 |
9 | RECOMBINANT INTERLEUKIN 11 | 6 | 71% | 1% | 5 |
10 | INTERLEUKIN 11 RECEPTOR ALPHA | 4 | 67% | 1% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Hematopoietic, immunomodulatory and epithelial effects of interleukin-11 | 1999 | 93 | 83 | 83% |
Interleukin-11: Review of molecular, cell biology, and clinical use | 1997 | 207 | 143 | 57% |
More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer | 2010 | 34 | 92 | 52% |
INTERLEUKIN-11 - A MULTIFUNCTIONAL GROWTH-FACTOR DERIVED FROM THE HEMATOPOIETIC MICROENVIRONMENT | 1994 | 176 | 44 | 70% |
PRECLINICAL BIOLOGY OF INTERLEUKIN-11 - A MULTIFUNCTIONAL HEMATOPOIETIC CYTOKINE WITH POTENT THROMBOPOIETIC ACTIVITY | 1995 | 34 | 25 | 80% |
The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes | 2007 | 15 | 25 | 44% |
IL-11 signaling as a therapeutic target for cancer | 2015 | 0 | 132 | 61% |
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis | 2001 | 26 | 12 | 42% |
Oprelvekin - A review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia | 1998 | 1 | 25 | 88% |
Regulation of osteoblast differentiation by interleukin-11 via AP-1 and Smad signaling | 2012 | 15 | 59 | 14% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GRP RECH CYTOKINES RECEPTEURS | 4 | 41% | 1.7% | 7 |
2 | AMB IMMUNOL | 1 | 50% | 0.2% | 1 |
3 | CLIN MED GENERALE | 1 | 50% | 0.2% | 1 |
4 | CRC EPITHELIAL BIOL GRP | 1 | 50% | 0.2% | 1 |
5 | ENDOCRINOL BONE METAB BREAST CANC | 1 | 50% | 0.2% | 1 |
6 | GLOBAL BIOSTAT CLIN TECHNOL | 1 | 50% | 0.2% | 1 |
7 | HERMAN B WELLS PEDIAT SECT PEDIAT HEMATOL | 1 | 50% | 0.2% | 1 |
8 | IMMUNOL IMMUNOL DIS MED | 1 | 50% | 0.2% | 1 |
9 | MED SURG PEDIAT SURG SECT | 1 | 50% | 0.2% | 1 |
10 | MOL MED PHARMACOGENOM | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000178536 | ONCOSTATIN M//LEUKEMIA INHIBITORY FACTOR//LEUKAEMIA INHIBITORY FACTOR |
2 | 0.0000133061 | IL 6 RECEPTOR//INTERLEUKIN 6 RECEPTOR//GP130 |
3 | 0.0000120554 | THROMBOPOIETIN//C MPL//MEGAKARYOCYTE |
4 | 0.0000062932 | CARDIOTROPHIN 1//CARDIOTROPHIN//ERK 1 AND 2 |
5 | 0.0000059036 | CILIARY NEUROTROPHIC FACTOR//CNTF//CNTFR ALPHA |
6 | 0.0000047637 | IMPLANTATION//ENDOMETRIAL RECEPTIVITY//ENDOMETRIUM |
7 | 0.0000041382 | RADIAT COUNTERMEASU PROGRAM//ARMED FORCES RADIOBIOL//ACUTE RADIATION SYNDROME |
8 | 0.0000039850 | BURN EXCISION//ANTITHROMBIN III CONCENTRATE//BURN TRAUMA UNIT SURG |
9 | 0.0000039255 | EX VIVO EXPANSION//CYTOKINE MEDIATED EXPANSION//AFT024 |
10 | 0.0000038640 | LONGEV SCI//HOSP GERIATR MED//TORAT MED |